Hopkins study: Immune cell receptor provides promising immunotherapy target

NCI, SITC immunotherapy fellowship calls for applications

NCI and the Society for Immunotherapy of Cancer are accepting applications for a one-year fellowship program beginning in July 2026.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies may fail in treating the disease, according to research led by researchers at Keck Medicine of USC.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor-induced type 1 diabetes using an existing class of autoimmune drugs.

July 11, 2025

Vol.51 No.27

Clinical Roundup

“Power surges” on cancer cell membranes may fuel progression of disease, Johns Hopkins study finds

In a bid to better understand how cancer cells power their explosive growth and spread, scientists at Johns Hopkins Medicine have shed new light on the location and function of power-generating waves on cancer cell membranes. The scientists say the waves, generated by rhythmic propagation of enzymes that produce energy from glucose, could potentially be used to better stage cancers and as targets for new cancer drugs.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Rare pancreatic cancer shows strong response to immunotherapy

New research shows that a rare group of pancreatic cancer patients responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type.

July 03, 2025

Vol.51 No.26

In Brief

Nicholas Jaidar named senior administrator for oncology at Johns Hopkins

Nicholas M. Jaidar was named senior administrator for oncology at the Department of Oncology at the Johns Hopkins University School of Medicine and the Johns Hopkins Hospital.

June 27, 2025

Vol.51 No.25

Hopkins study: Immune cell receptor provides promising immunotherapy target

YOU MAY BE INTERESTED IN

NCI, SITC immunotherapy fellowship calls for applications

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

“Power surges” on cancer cell membranes may fuel progression of disease, Johns Hopkins study finds

Rare pancreatic cancer shows strong response to immunotherapy

Nicholas Jaidar named senior administrator for oncology at Johns Hopkins

Renew today!

Subscriber content

Never miss an issue!

Login